enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company’s stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total value of $717,810.00. Following the transaction, the insider now owns 3,036,153 shares of the company’s stock, valued at $45,542,295. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
De Solidarite Des Travai Fonds also recently made the following trade(s):
- On Thursday, April 18th, De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock. The stock was sold at an average price of $15.01, for a total transaction of $68,670.75.
enGene Stock Performance
NASDAQ:ENGN opened at $15.26 on Wednesday. The stock has a 50 day moving average price of $16.27. enGene Holdings Inc. has a 52 week low of $6.69 and a 52 week high of $43.00.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on enGene
Hedge Funds Weigh In On enGene
Several institutional investors have recently bought and sold shares of ENGN. Vivo Capital LLC bought a new position in enGene in the 4th quarter worth $6,264,000. BVF Inc. IL bought a new position in shares of enGene in the fourth quarter worth about $20,777,000. Omega Fund Management LLC acquired a new position in shares of enGene during the 4th quarter worth about $10,441,000. Finally, Fcpm Iii Services B.V. bought a new stake in enGene during the 4th quarter valued at approximately $80,097,000. 64.16% of the stock is currently owned by institutional investors.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- Stock Average Calculator
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Are Penny Stocks a Good Fit for Your Portfolio?
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Ride Out The Recession With These Dividend Kings
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.